Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is supported by a resilient core HIV franchise anchored by Biktarvy and broader HIV assets, which the company expects to remain a strong foundation for valuation through at least the end of the decade despite some IRA-related pricing pressure and the need for life-cycle initiatives. Its HCV business, while in secular decline, still offers meaningful cash generation through share and pricing stability, with sustainable patient volumes expected to contribute more than $12B in cash flows over the next decade, while the company’s extensive worldwide sales and marketing infrastructure and tiered access model strengthen durability and global reach. The bullish case is further reinforced by an expanding oncology pipeline led by Yescarta/Tecartus and Trodelvy, alongside the emerging growth from Yeztugo, which reached $166M in 1Q26 and was guided to $1B in FY26, suggesting that recent M&A and pipeline execution can offset legacy headwinds and drive long-term growth.

Gilead Sciences is facing a negative fundamental setup because the market’s key debate around PrEP persistence has yet to inflect, and the stock has already underperformed this month with shares down 7.5% MTD versus peers that were flat, suggesting investor skepticism about the durability of HIV-driven growth. Although the broader HIV franchise remains healthy and HIV growth is now expected at 8% versus 6% previously, that strength is partly offset by 2% headwinds from drug pricing agreements and ACA changes, while management still needs clearer evidence of accelerating scripts, meaningful buy-and-bill adoption, or new growth legs outside HIV. The company’s longer-term catalysts are still largely ahead in 1Q26, 1H26, and 2H26, so near-term fundamentals appear dependent on pipeline execution rather than current cash-flow momentum, which leaves the outlook constrained despite oncology expansion efforts through Yescarta/Tecartus and Trodelvy.